BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 2480664)

  • 1. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder.
    Vincent A; Lang B; Newsom-Davis J
    Trends Neurosci; 1989 Dec; 12(12):496-502. PubMed ID: 2480664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune disorders of neuromuscular transmission.
    Mahadeva B; Phillips LH; Juel VC
    Semin Neurol; 2008 Apr; 28(2):212-27. PubMed ID: 18351523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome.
    Takamori M; Takahashi M; Yasukawa Y; Iwasa K; Nemoto Y; Suenaga A; Nagataki S; Nakamura T
    J Neurol Sci; 1995 Nov; 133(1-2):95-101. PubMed ID: 8583238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome.
    Mason WP; Graus F; Lang B; Honnorat J; Delattre JY; Valldeoriola F; Antoine JC; Rosenblum MK; Rosenfeld MR; Newsom-Davis J; Posner JB; Dalmau J
    Brain; 1997 Aug; 120 ( Pt 8)():1279-300. PubMed ID: 9278623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome.
    Lang B; Pinto A; Giovannini F; Newsom-Davis J; Vincent A
    Ann N Y Acad Sci; 2003 Sep; 998():187-95. PubMed ID: 14592874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes.
    Lennon VA; Kryzer TJ; Griesmann GE; O'Suilleabhain PE; Windebank AJ; Woppmann A; Miljanich GP; Lambert EH
    N Engl J Med; 1995 Jun; 332(22):1467-74. PubMed ID: 7739683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [P/Q-type Calcium Channel Antibodies in Lambert-Eaton Myasthenic Syndrome].
    Kitanosono H; Shiraishi H; Motomura M
    Brain Nerve; 2018 Apr; 70(4):341-355. PubMed ID: 29632282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.
    Flink MT; Atchison WD
    J Bioenerg Biomembr; 2003 Dec; 35(6):697-718. PubMed ID: 15000529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Autoantibody against the presynaptic P/Q-type voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome].
    Sakai W; Nakane S; Matsuo H
    Brain Nerve; 2013 Apr; 65(4):441-8. PubMed ID: 23568992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    Schoser B; Eymard B; Datt J; Mantegazza R
    J Neurol; 2017 Sep; 264(9):1854-1863. PubMed ID: 28608304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to calcium channel and synaptotagmin in Lambert-Eaton myasthenic syndrome.
    Takamori M; Komai K; Iwasa K
    Am J Med Sci; 2000 Apr; 319(4):204-8. PubMed ID: 10768604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lambert-Eaton myasthenic syndrome: a review.
    Newsom-Davis J
    Monogr Allergy; 1988; 25():116-24. PubMed ID: 2845259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lambert-Eaton syndrome antibodies target multiple subunits of voltage-gated Ca2+ channels.
    Hajela RK; Huntoon KM; Atchison WD
    Muscle Nerve; 2015 Feb; 51(2):176-84. PubMed ID: 24862203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.
    Sabater L; Titulaer M; Saiz A; Verschuuren J; Güre AO; Graus F
    Neurology; 2008 Mar; 70(12):924-8. PubMed ID: 18032743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system.
    Voltz R; Carpentier AF; Rosenfeld MR; Posner JB; Dalmau J
    Muscle Nerve; 1999 Jan; 22(1):119-22. PubMed ID: 9883867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis.
    Takamori M
    J Neuroimmunol; 2008 Sep; 201-202():145-52. PubMed ID: 18653248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome.
    Motomura M; Lang B; Johnston I; Palace J; Vincent A; Newsom-Davis J
    J Neurol Sci; 1997 Mar; 147(1):35-42. PubMed ID: 9094058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular immunology of voltage-gated calcium channel and Lambert-Eaton myasthenic syndrome].
    Iwasa K; Komai K; Yasukawa Y; Maruta T; Takamori M
    Nihon Rinsho; 1997 Dec; 55(12):3322-30. PubMed ID: 9436458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lambert-Eaton myasthenic syndrome, an immune pathology of neuromuscular junctions].
    Honnorat J
    Bull Acad Natl Med; 2014 Feb; 198(2):243-54; discussion 255. PubMed ID: 26263702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
    Titulaer MJ; Lang B; Verschuuren JJ
    Lancet Neurol; 2011 Dec; 10(12):1098-107. PubMed ID: 22094130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.